Syndax Pharmaceuticals UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you for joining. It is a great pleasure to have Syndax Pharmaceuticals. My name is David Dai. I am a biotech analyst here at UBS, and welcome to our inaugural UBS conference here in London. With Syndax here, we have Michael Metzger, our Chief Executive Officer, and also Nick Botwood, Chief Medical Officer, with us today. We would love to dive into some of the stuff that Syndax is working on. Maybe a quick background for anyone who is new to the story. Syndax is a very exciting biotech company that is developing two commercial stage programs right now. They have one menin inhibitor that is on the market for about over a year now, generating pretty good sales so far. We will dive into that in a bit, and we are seeing continued growth.
They also have another program called Niktimvo for treatment of GVHD, with potential of moving to a frontline setting, and data coming up next year as well. Pretty exciting stuff. Today we are just going to dive into these programs as well as some of the pipeline, the stuff that you guys are also working on as well. Let me just start things off, Michael and Nick, maybe give us a quick overview of Syndax, the key stories, as well as the two commercial programs, Revuforj and Niktimvo.
First of all, thank you, David. Thanks to UBS for having us. Always a pleasure, and your first foray into the London conferences. Look, Syndax is a very exciting story. I think we have, as you pointed out, we are one of the few companies that has two commercial products. We grew them from and developed them on our own for many years and brought them forward, and now have launched them into the market. So with success and leadership, both in menin inhibition as well as the CSF1R inhibition for GVHD. The current business is growing very nicely. I think we have launched the relapse refractory disease, and now we are moving into frontline opportunities, which are considerably larger, multi-billion dollar opportunities, where we are really revolutionizing treatment for these patients. That is the most exciting thing.
We have seen the growth of the business from a clinical stage now to a fully integrated commercial organization with growth ahead of us. The story that we are excited about not only extends to these programs, but we also have an early pipeline which is emerging, which will hopefully have data in the next year or so. I should say, but those programs really are emblematic of who we are as a company and the growth engine and the development engine to now leverage the platform that we have built as a company. Very exciting times for us, and a lot to talk about today, of course, on our assets.
Great. No, this is fantastic. Maybe start things off just talking about Revuforj, right?
Sure. It's your key program in the space.
Last quarter, third quarter, you had pretty good numbers. You're looking at about $60.7 million with about 11% quarter-over-quarter growth. At the same time, you're actually seeing continued growth in terms of the patient starts. Maybe just help us understand a little more around what are you seeing in terms of the adoption trends, and what gives you the confidence that you'll see continued growth?
Well, the very interesting aspect of this program, I would say, is how we've treated patients to really transform KMT2A acute leukemia and NPM1 mutant leukemia in terms of how we treat the patients. What's so remarkable about that is the fact that we've been able to get patients to a high remission rate, right? So many of our patients get into remission, many more before Revuforj came along. Not only that, but we can get them into a transplant state, help them get into a transplant, and then bring them back and give them maintenance treatment and extend their remissions for months, if not years. I think that's the promise of Revuforj. We've been able to show that in the commercial market. Now we have sales to kind of back that up at $61 million on the quarter, a growing base of business.
We're not only showing that we can really take dominant share of new patient starts, but also treat them for longer duration, get them to many more patients to a transplant, and then keep them on for months. I think that is a sea change for both KMT2A and NPM1 disease, never before. We're very optimistic about what we can do with not only relapse refractory disease, but now going in combination and treating patients earlier and earlier, rates of remission go up, and we start to see that grow. As we approach frontline, we now have data, we'll talk about some of that data today, the ability to treat patients in combination, and what does that mean for the future of Revuforj in terms of growth in frontline indications and best-in-class profile.
We are really solidifying our position, and each quarter you see that growth.
Yeah. Interesting you mentioned physicians are treating patients earlier and earlier.
Yes. Even in your relapsed refractory setting here, what is driving that adoption there in frontline?
Is this efficacy, safety, or convenience? What are some of the key things that you see in terms of getting the physicians to treat patients earlier and earlier?
Yeah. Maybe, Nick, do you want to?
I'd be happy to, and thank you, David Dai, for having us firstly, and it's my hometown, so nice to be here with you.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
